Animal Vaccines Market Share, Size, Trends, Industry Analysis Report, By Product (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines); By Type; By Disease; By Route of Administration; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 119
- Format: PDF
- Report ID: PM1971
- Base Year: 2023
- Historical Data: 2019-2021
Report Outlook
The global animal vaccines market was valued at USD 13.34 billion in 2023 and is expected to grow at a CAGR of 9.90% during the forecast period. Increasing livestock populations, disease outbreaks, and the continuous introduction of technologically advanced vaccinations have changed the dynamics of the industry. Due to the rise in pet ownership in industrialized nations and the increase in poultry and cattle in emerging economies, the market is anticipated to expand gradually.
To Understand More About this Research: Request a Free Sample Report
The incidence of zoonotic diseases is increasing rapidly worldwide, with some attributing the transmission of novel coronavirus to humans from pets. The World Health Organization (WHO) reports that zoonotic diseases cause nearly one billion cases of various illnesses yearly, with approximately 60% of infectious diseases in developing countries originating from animals.
Zoonotic diseases are on the rise worldwide, and there is a growing belief that the novel coronavirus originated from animals. The World Health Organization reports that zoonoses cause nearly one billion cases of various diseases yearly and account for almost 60% of all infectious diseases in developing countries with animal origins.
Vaccines undergo extensive testing and analysis for several years before they are developed. The post-trial stage is the most critical phase, determining the newly developed vaccine's success and acceptance rate. Animal vaccines play a vital role in maintaining and reducing the frequency of animal diseases, which is crucial as society relies on them. The top three animal vaccines with the highest usage rates are for equine influenza virus, foot, mouth disease, and rabies, which help preserve the health of animals and humans.
The primary growth drivers for this industry are rising livestock populations, expanding animal husbandry, and commercializing animal products. Moreover, the proliferation of zoonotic and animal illnesses and the ongoing release of technologically sophisticated vaccinations have fueled market expansion. Several difficulties and restraints will drive the growth of the market. Factors like the expensive cost of vaccine storage constrain market growth. Also, the lack of knowledge about animal health and the likelihood that veterinary vaccinations will harm human or other animal health are significant obstacles to the overall expansion of the global animal vaccine industry.
The global market is anticipated to experience a setback due to the outbreak of COVID-19, which has caused several countries to suspend animal vaccination programs. Nevertheless, some countries are developing vaccines for pets to prevent the transmission of the virus from humans. Russia recently registered Carnivac-COV, which is believed to be the first COVID-19 vaccine developed for animals. Despite this, COVID-19 is projected to have an adverse effect on the market.
For Specific Research Requirements, Request for a Customized Report
Industry Dynamics
Growth Drivers
The global market is experiencing growth due to several factors, including the rise in zoonotic diseases worldwide in recent decades and the expanding poultry, aquaculture, and pork industries that significantly contribute to the economies of many countries. Additionally, the market is projected to grow further with the introduction of new vaccine technologies and government efforts to vaccinate pets.
The aquaculture industry thrives in several countries, with 51.3 million metric tons of aquatic species produced via inland aquaculture in 2018. China leads the pack by accounting for 66% of the world's marine products and boasts the largest aquaculture industry worldwide. These factors have resulted in the expansion of the global market. In recent times, companies have made significant strides in the industry, such as developing new vaccines, mergers, and acquisitions, and obtaining funding. Indian Immunological Limited (IIL) collaborated with the Indian Veterinary Research Institute (IVRI) to create a Swine Fever vaccine named Raksha Class, using cell culture technology which was released in 2020.
Report Segmentation
The market is primarily segmented based on product, type, disease, route of administration and region.
|
By Products |
By Type |
By Disease |
By Route of Administration |
By Region |
|
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
The attenuated live vaccines segment is expected to witness the highest growth share in 2022
In 2022, the segment generating the highest revenue was attenuated live vaccines. These vaccines stimulate a wider range of immune responses and can provide better immunity than conventional vaccines. Additionally, they reduce the need for additional orally-administered vaccines, providing long-lasting and rapid onset of immunity. All of these factors contribute to the growth of the animal vaccines market.
The forecast period is expected to grow higher in the recombinant vaccine segment. These vaccines are designed to reduce the risk of pathogenicity after vaccination in pets. With the ability to carry multiple gene inserts, recombinant vaccines are expected to be effective against various viral strains. Additionally, these vaccine formulations eliminate the need for adjuvants, resulting in increased vaccine viability and stability.
The subcutaneous segment is expected to witness the largest growth share in 2022
The subcutaneous segment largely dominated the animal vaccines market in 2022. Most of an animal's subcutaneous injection sites are found in the neck and behind the shoulder blades. The market expansion is projected to be aided by the simplicity of administering medications subcutaneously because the body can progressively absorb them. Moreover, animals have less discomfort and a quicker delivery method using the subcutaneous route. Moreover, subcutaneous injectable administration is simpler to teach veterinary practitioners. Currently,the most popular forms of administration in animals are intramuscular and subcutaneous. These elements support market expansion.
The ruminant vaccines segment accounted to witness fastest significant market in 2022
The ruminant vaccines segment generating the fastest revenue in 2022. This growth is attributed to an increase in livestock population, supportive government initiatives, and the emergence of diseases in cattle and sheep. However, the decline in zoonotic diseases due to the efforts of FAO and its partners in over 50 countries is expected to bolster the segment's growth prospects.
On the other hand, the poultry vaccines segment is predicted to grow at the fastest pace, fueled by the rising consumption of poultry products. The segment's growth potential is further augmented by using a wide range of vaccines, pharmaceuticals, and feeds to produce higher-quality poultry products.
North America is dominate the market in 2022
North America dominated the market and generated the highest revenue in 2022. The more significant share can be due to the greater frequency of livestock and zoonotic illnesses, which result in large-scale animal mortality.
The market growth is expected to be fueled by established pharmaceutical companies consistently working to commercialize their vaccines and expand their global reach. Furthermore, in countries such as the U.S., animal vaccines are administered to both food and pet animals, contributing to the growth of the vaccine market in the region.
During the forecast period, the Asia Pacific region is predicted to be the fastest-growing region globally, driven by government initiatives in emerging economies and significant poultry, aquaculture, and pork industries in countries like China. Countries are planning mass immunization programs for food animals. India is the world's largest vaccine producer, all of which are expected to boost the market growth in the region further.
Competitive Insight
Some key players in the market are participating in R&D to develop new advanced vaccines for pet animals and food animals. The major key players operating in the market include Biogénesis Bagó, Boehringer Ingelheim International GmbH, Elanco, Merck & Co., Inc., Ceva, Intas Pharmaceuticals Ltd., Indian Immunologicals Ltd., Neogen Corporation, Phibro Animal Health Corporation, Ourofino Saúde Animal, Virbac, and Zoetis.
Recent Developments
- In June 2021, the United Kingdom announced plans to open a U.K. Animal Vaccine Production and Innovation Centre in Surrey. This facility aims to speed up the development of livestock vaccines and stop the spread of viral illnesses like coronavirus.
- In September 2022 the second phase of the National Animal Disease Control Programme for vaccination against Foot and Mouth Disease was formally begun by the Nagaland Livestock Development Board (NLDB), which oversees the animal husbandry department and veterinary services in Nagaland.
- In September 2021, Virbac and Jectas innovators entered into a collaboration to develop animal health vaccines.
- In February 2021, A first framework agreement between CevaSanté Animale and INRAE was signed to strengthen their veterinary health collaboration. It also involves testing vaccinations and anti-infective medications, as well as several other forms of collaboration.
Animal Vaccines Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 14.61 billion |
|
Revenue forecast in 2032 |
USD 31.07 billion |
|
CAGR |
9.90% from 2024 - 2032 |
|
Base year |
2023 |
|
Historical data |
2019 - 2021 |
|
Forecast period |
2024 - 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
By Product, By Type, By Disease, By Route of Administration, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Biogénesis Bagó, Boehringer Ingelheim International GmbH, Elanco, Merck & Co., Inc., Ceva, Intas Pharmaceuticals Ltd., Indian Immunologicals Ltd., Neogen Corporation, Phibro Animal Health Corporation, Ourofino Saúde Animal, Virbac, and Zoetis. |
Navigate through the intricacies of the 2032 Animal Vaccines Market with precision, thanks to the comprehensive statistics on market share, size, and revenue growth rate assembled by Polaris Market Research Industry Reports. This thorough analysis not only provides a glimpse into the historical context but also extends its reach with a market forecast outlook until 2032. Immerse yourself in the richness of this industry analysis by securing a complimentary PDF download of the sample report.
Browse Our Top Selling Reports
Liver Metastases Treatment Market Size, Share 2024 Research Report
Cytotoxic Drugs Market Size, Share 2024 Research Report
Antibiotic Resistance Market Size, Share 2024 Research Report
Benzodiazepine Drugs Market Size, Share 2024 Research Report
FAQ's
The global animal vaccines market size is expected to reach USD 31.07 billion by 2032.
Key players in the animal vaccines market are Biogénesis Bagó, Boehringer Ingelheim International GmbH, Elanco, Merck & Co., Inc.
North America contribute notably towards the global animal vaccines market.
The global animal vaccines market expected to grow at a CAGR of 9.8% during the forecast period.
The animal vaccines market report covering key segments are product, type, disease, route of administration and region.
